GlassScriptPhysician profile
Tabitha Manero Marek
NPI 1245644814
$6,238.67
in general payments reported to CMS, 2019-2025
35 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $960 · 2020: $822 · 2021: $630 · 2022: $1,467 · 2023: $1,459 · 2024: $902.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,354 · Education: $6.65.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,353.88 |
| Education | $6.65 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,488.27 | 2019-2024 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $705.21 | 2021-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $438.17 | 2022-2024 | |
| Lilly USA, LLC | $432.98 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Amgen INC. | $402.68 | 2019-2024 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $367.97 | 2019-2023 | Gardasil 9, Vaxneuvance, Pneumovax 23 |
| Astrazeneca Pharmaceuticals LP | $351.54 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Pfizer INC. | $306.16 | 2019-2024 | |
| Abbott Laboratories | $228.53 | 2022-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Biohaven Pharmaceutical Holding Company LTD. | $225.60 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $208.07 | 2020-2021 | |
| Amarin Pharma, INC. | $141.52 | 2019-2022 | |
| Glaxosmithkline, LLC. | $133.20 | 2019-2024 | Shingrix |
| Takeda Pharmaceuticals U.S.A., INC. | $110.58 | 2019-2024 | Trintellix |
| Shield Therapeutics INC | $105.64 | 2023-2024 | Accrufer |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $94.37 | 2019-2024 | Jardiance |
| Janssen Pharmaceuticals, INC | $69.32 | 2020-2023 | Spravato |
| Hologic Sales and Service, LLC | $42.73 | 2022 | |
| Allergan, INC. | $39.14 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $38.23 | 2021 | |
| Esperion Therapeutics, INC. | $32.95 | 2020-2024 | Nexletol |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.49 | 2019-2024 | Xifaxan, Trulance |
| Edwards Lifesciences Corporation | $30.11 | 2023 | Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Daiichi Sankyo INC. | $27.41 | 2024 | Injectafer |
| Axsome Therapeutics, INC. | $26.31 | 2024 | Auvelity |
| Shire North American Group INC | $21.69 | 2019 | |
| Astellas Pharma US INC | $20.58 | 2022 | |
| Viiv Healthcare Company | $18.87 | 2022 | |
| Eisai INC. | $18.68 | 2020 | |
| Horizon Therapeutics Plc | $16.62 | 2022 | |
| Impel Pharmaceuticals INC. | $14.48 | 2022 | |
| Genentech USA, INC. | $13.02 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.68 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.56 | 2019 | |
| Idorsia Pharmaceuticals US INC | $12.31 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tabitha Marek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.